ChinaBio(R) LLC: China Leads Emerging Nations in Pharma M&A

by Richard Daverman, PhD

December 12, 2012 -- Drug companies are increasing their M&A spending in emerging markets, and China is garnering the lion’s share of activity, according to data from Thomson Reuters. All together, including capital from both overseas and domestic drug manufacturers, M&A in emerging countries has totaled $20 billion this year. That’s a jump of 67% over last year. China deals were responsible for one-third of the total: $6.8 billion. More details....